Folate-Imaging Agent Conjugates for Early Inflammation Response Prediction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current biologic therapies for autoimmune and inflammatory diseases lack a reliable clinical marker to predict patient response, leading to subjective assessment methods that often result in delayed identification of nonresponders and increased costs due to irreversible damage.
Innovation Solution
The use of folate-imaging agent conjugates, such as 99mTc-EC20, to predict a patient's response to anti-inflammatory drugs by targeting activated macrophages, allowing for early identification of responders before clinical changes are observable.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Loss of time
If subjective criteria (assessment of pain, coloration and swelling, radiographic analysis) are used to determine treatment response, then physicians can assess patient condition without additional tools, but identification of nonresponders is delayed until 4-6 months after therapy initiation
Solution Approach 1:
The folate-imaging agent conjugate is administered early in the treatment course (before 4-6 months) to predict future treatment response. This preliminary imaging action allows physicians to identify nonresponders before irreversible damage occurs, resolving the time delay inherent in traditional subjective assessment methods while maintaining adequate measurement precision through quantitative imaging data
2Reliability
If biologic therapies are administered to patients with inflammatory diseases, then treatment efficacy is enhanced with increased speed of onset, but 40% of patients fail to respond and irreversible damage may occur
Solution Approach 1:
The imaging conjugate performs preliminary assessment of treatment response potential before significant irreversible damage occurs. By predicting which patients will respond to biologic therapy versus those who will not, the system allows physicians to avoid or switch therapies early, preventing the 40% failure rate from resulting in irreversible harm
Solution Approach 2:
The folate-receptor targeted imaging provides feedback on macrophage activation status and treatment response prediction. This feedback mechanism enables continuous monitoring and adjustment of therapy, transforming the unreliable trial-and-error approach into a guided treatment strategy that reduces harmful outcomes
3Measurement precision
If folate-imaging agent conjugates are used to predict treatment response, then accurate forecasting is achieved before clinical changes are detectable, but additional imaging procedures and costs are incurred
Solution Approach 1:
The folate-imaging agent conjugate serves multiple functions: it targets activated macrophages specifically, provides quantitative imaging data for response prediction, and can be integrated into existing nuclear medicine infrastructure. This multi-functionality achieves high measurement precision without requiring entirely new complex devices, leveraging established imaging technologies
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enables accurate forecasting of treatment response, reducing costs and morbidity by identifying patients who will benefit from therapy before irreversible damage occurs.
Implementation Method 1
the folate receptor β, a glycosylphosphatidylinositol anchored glycoprotein, is uniquely over-expressed on the surface of these activated macrophages, folate receptor-targeted imaging agents have been recently exploited to visualize sites of activated macrophage accumulation
Implementation Method 2
99mTc-EC20, a folate receptor-targeted radiopharmaceutical, has proven particularly useful for these imaging applications in that uptake of 99mTc-EC20 has been observed to correlate directly with severity of arthritis symptoms
Data Source
AI summary
The invention relates to methods and compositions for the selection of patients for therapy with an anti-inflammatory drug. More particularly, the invention relates to compositions comprising folate-imaging agent conjugates for the selection of patients for therapy with an anti-inflammatory drug, and methods and uses therefor.